The Lexicon Pharmaceuticals’ (LXRX) “Buy” Rating Reiterate at HC Wainwright

The Lexicon Pharmaceuticals’ (LXRX) “Buy” Rating Reiterate at HC Wainwright

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Wednesday.

LXRX has been the subject of a number of other research reports. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Wednesday, October 5th. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Lexicon Pharmaceuticals in a report on Tuesday, September 20th. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, September 9th. TheStreet lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday, September 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. Lexicon Pharmaceuticals has a consensus rating of “Hold” and an average target price of $23.86.

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) traded up 0.97% during midday trading on Wednesday, reaching $16.69. 183,588 shares of the company were exchanged. The firm’s market capitalization is $1.74 billion. Lexicon Pharmaceuticals has a 52 week low of $7.65 and a 52 week high of $19.62. The firm has a 50-day moving average of $16.25 and a 200 day moving average of $15.53.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, November 1st. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.14. Lexicon Pharmaceuticals had a negative net margin of 11.87% and a negative return on equity of 9.46%. The business earned $27.70 million during the quarter, compared to analyst estimates of $9.68 million. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. The company’s revenue for the quarter was up 4763.2% compared to the same quarter last year. On average, equities research analysts expect that Lexicon Pharmaceuticals will post ($1.57) EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of LXRX. Swiss National Bank boosted its position in Lexicon Pharmaceuticals by 9.5% in the second quarter. Swiss National Bank now owns 87,214 shares of the biopharmaceutical company’s stock worth $1,252,000 after buying an additional 7,600 shares during the last quarter. Quantbot Technologies LP boosted its position in Lexicon Pharmaceuticals by 12.3% in the second quarter. Quantbot Technologies LP now owns 13,999 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,529 shares during the last quarter. California State Teachers Retirement System boosted its position in Lexicon Pharmaceuticals by 0.7% in the second quarter. California State Teachers Retirement System now owns 88,627 shares of the biopharmaceutical company’s stock worth $1,272,000 after buying an additional 602 shares during the last quarter. Capital Fund Management S.A. bought a new position in Lexicon Pharmaceuticals during the second quarter worth approximately $283,000. Finally, American Century Companies Inc. bought a new position in Lexicon Pharmaceuticals during the second quarter worth approximately $2,194,000.

Lexicon Pharmaceuticals Company Profile

Related posts

Leave a Comment